Clinical trials: Lung Cancer Small Cell Lung Cancer (SCLC)
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage…
- Conditions
- Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer, EGFR Mutation-Related Tumors
- Trial name
- NCT04304638
- Testing
- radiation or chemo-radiation, EGFR-TKI Inhibitor
- Volunteers
- 450 people
- Sponsor
- Chinese Academy of Medical Sciences
Bronchial Dysplasia, Tobacco Smoking
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
The goal of this clinical research study is to determine whether the PD-1 inhibitor (Programmed cell death protein 1) nivolumab improves premalignant bronchial dysplastic lesions in subjects that are at high risk for the…
- Conditions
- Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
- Trial name
- NCT03347838
- Testing
- Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Colorado, Denver
Non-Small Cell Lung Cancer
Effect of Two Different Preoperative Training Densities in Patients With Non-small-cell Lung Cancer Before Lung Resection Surgery
Pulmonary resection surgery is currently the recommended curative treatment for early stages of non-small cell lung cancer. The implementation of preoperative respiratory rehabilitation programs has shown beneficial results on…
- Trial name
- Preo-Dens (NCT03936764)
- Testing
- Preoperative Pulmonary Rehabilitation
- Where
- France
- Volunteers
- 36 people
- Sponsor
- ADIR Association
Small Cell Lung Cancer
Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)
The purpose of this study is to determine treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.
- Trial name
- NCT00418743
- Where
- 24 sites in France
- Volunteers
- 138 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Lung Cancer
The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer
Lung cancer is currently the leading cause of cancer-related mortality worldwide, and the dominant histopathology is non-small cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT05541744)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Lung Cancer
Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- CONVERT (NCT00433563)
- Testing
- Once daily radiotherapy, Twice daily radiotherapy
- Where
- United Kingdom
- Volunteers
- 547 people
- Sponsor
- The Christie NHS Foundation Trust
Stage IV NSCLC
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
This pilot phase I trial aims to investigate the safety and tolerability of anti-programmed cell death-1 (PD-1) monoclonal antibody Sintilimab (also called IBI308) in combination with concurrent stereotactic body radiation…
- Trial name
- NCT03812549
- Testing
- Sintilimab, stereotactic body radiation therapy, Low Dose Radiotherapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sichuan University
Non Small Cell Lung Cancer
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior…
- Trial name
- NCT05457049
- Testing
- Molecular residual disease test
- Where
- 5 sites in China
- Volunteers
- 180 people
- Sponsor
- Guangdong Association of Clinical Trials
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
The SABR-ATAC trial (Stereotactic Ablative Radiotherapy and anti-TGFB Antibody Combination) is a phase I/II trial that studies the side effects and efficacy of fresolimumab, an anti-transforming growth factor beta (TGFB)…
- Trial name
- NCT02581787
- Testing
- Fresolimumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Maximilian Diehn
Resectable Non-small Cell Lung Cancer
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
- Trial name
- NCT05247684
- Testing
- AK112, Carboplatin, Cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Squamous Cell Lung Cancer
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib.
- Trial name
- ECLIPSE (NCT01082549)
- Testing
- gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib
- Where
- 142 sites in United States, Belgium and 12 more
- Volunteers
- 780 people
- Sponsor
- Sanofi
Non-Small Cell Lung Carcinoma, Small Cell Lung Cancer
Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients
The majority of lung cancer patients have a tumor-derived genetic alteration in circulating plasma DNA that could be exploited as a diagnostic tool.
- Trial name
- NCT00213798
- Testing
- Biopsy samples
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
NSCLC
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients.
- Trial name
- NCT04390984
- Testing
- Apatinib Mesylate, Gefitinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer
Web-based Intervention for Lung Cancer Patients and Their Informal Caregivers
The purpose of this study is to find out if patients with lung cancer and their main informal caregiver (person providing physical, emotional, or financial support) are helped by getting information, support, and decision making…
- Trial name
- NCT00365963
- Testing
- Comprehensive Health Enhancement Support System
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- University of Wisconsin, Madison
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Lung Adenocarcinoma
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
The goal of this Phase II clinical trial (The PHOENIX Study) is to evaluate if the combination of QL1706 (Iparomlimab and Tuvonralimab), bevacizumab, and chemotherapy can treat patients with TKI-refractory, driver-gene positive…
- Trial name
- PHOENIX (NCT07416058)
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Where
- 2 sites in China
- Volunteers
- 61 people
- Sponsor
- Guangdong Association of Clinical Trials
Multiple Brain Metastases, Non-small-cell Lung Cancer
Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
1. Verify the effect of Erlotinib concurrent whole-brain radiation therapy as first-line treatment for patients with multiple brain metastases from non-small-cell lung cancer to compare with WBRT alone. 2.
- Trial name
- NCT01887795
- Testing
- Erlotinib, WBRT
- Where
- China
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-squamous Non-small Cell Lung Cancer
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
This is a non-randomized, open-label, single arm phase II trial of the combination of bevacizumab and ixabepilone in patients with advanced- or metastatic non-squamous NSCLC progressive after first or second-line therapy.
- Trial name
- NCT01057212
- Testing
- ixabepilone, bevacizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Non-small Cell Lung Cancer
Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer
By exploring the feasibility, effectiveness and safety of neoadjuvant therapy with Sintilimab combined with platinum-containing chemotherapy in patients with resectable Stage ⅡB-ⅢA NSCLC, we will provide new treatment options and…
- Trial name
- NCT05170581
- Testing
- Sintilimab Combined with Platinum-containing Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Non-small Cell Lung Cancer, Breast Cancer
Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study
Sometimes, cancer comes back after it has been successfully treated-a situation called recurrent cancer. When recurrent cancer is suspected, the standard approach to diagnosis is to perform a combination of imaging tests, such as…
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer, Ovarian Cancer
- Trial name
- PETREC (NCT00686465)
- Testing
- PET/CT scan
- Where
- 4 sites in Canada
- Volunteers
- 101 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.